Linezolid optic neuropathy

Curr Opin Ophthalmol. 2023 Nov 1;34(6):481-486. doi: 10.1097/ICU.0000000000000995. Epub 2023 Aug 21.

Abstract

Purpose of review: In this article, we reviewed 67 reported cases of linezolid optic neuropathy and describe the common characteristics and expectations for recovery with an emphasis on recent findings in the literature.

Recent findings: Linezolid classically causes a reversible, duration-dependent optic neuropathy. However, in our review, we found only 66.7% of patients recovered complete visual function. Vision loss most commonly affected visual acuity followed by visual field and color vision. We also found patients taking higher doses of linezolid experienced full recovery less often, suggesting a dose-dependent component of linezolid optic neuropathy. Linezolid use has increased in frequency and duration, especially in the treatment of drug-resistant tuberculosis, and data indicate that these patients experience lower rates of complete vision recovery compared with patients taking linezolid for other indications.

Summary: Linezolid is an effective medication for treating drug-resistant infections; however, it may result in optic neuropathy. It is reasonable for patients on linezolid to undergo screening examinations, especially those on higher doses or for prolonged duration of therapy.

Publication types

  • Review

MeSH terms

  • Anti-Infective Agents*
  • Humans
  • Linezolid / adverse effects
  • Optic Nerve
  • Optic Nerve Diseases* / chemically induced
  • Optic Nerve Diseases* / diagnosis
  • Vision Disorders

Substances

  • Linezolid
  • Anti-Infective Agents